HTBX Description — Heat Biologics Inc
NightHawk Biosciences is a biopharmaceutical company focusing on the development and commercialization of therapies that arm the immune system against a range of diseases including cancer and infectious disease. Co.'s gp96 platform and RapidVax® platforms are designed to utilize the ability of gp96 to constitutively transport predefined antigens of interest to antigen presenting cells that in turn stimulate an antigen-specific immune response that includes B cells, CD4+ T-cells, and cytotoxic CD8+ T-cells. HS-110 (viagenpumatucel-L), an allogeneic therapy, is Co.'s main gp96 asset having completed Phase 2 enrollment of a non-small cell lung cancer clinical trial.